A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood (UCB) Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies following Myeloablative Therapy
Latest Information Update: 13 Feb 2019
At a glance
- Drugs Carlecortemcel-L (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ExCELL
- Sponsors Teva Pharmaceutical Industries - Gamida-Cell (JV)
- 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2013 Based on interim results from this trial, the FDA has recommended that an additional phase III trial be conducted for registration, according to a Gamida Cell media release.